Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells
Yıl: 2020 Cilt: 17 Sayı: 1 Sayfa Aralığı: 49 - 55 Metin Dili: İngilizce DOI: 10.4274/tjps.galenos.2018.49389 İndeks Tarihi: 27-11-2020
Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells
Öz: Objectives: Chronic myelogenous leukemia (CML) is a type of blood cancer that is initially treated with imatinib (first Abl kinase inhibitor). However,some patients with CML develop imatinib resistance. Several new generation drugs have been developed, but do not overcome this problem.Glycyrrhetic acid (GA) is a plant-derived pentacyclic triterpenoid that exhibits multiple pharmacological properties for the treatment of cancers. Thecurrent study aimed to investigate the effects of GA on the K562 cell line (Bcr-Abl positive leukemia).Materials and Methods: The MTT cell proliferation assay was employed to evaluate the cytotoxic effect of GA compared with imatinib (positivecontrol) against leukemia and normal blood cells. For detection of cell death, an apoptotic/necrotic/healthy assay was performed against the K562cell line. To investigate the kinase inhibitory activity of GA, the Abl1 kinase profiling assay and a molecular docking study were performed.Results: GA showed Abl kinase inhibitory activity with an IC50 value of 29.2 μM and induced apoptosis in the K562 cell line after 6 h of treatment.Conclusion: The current findings indicate that this class of plant extract could be a potential candidate for treatment of CML.
Anahtar Kelime: Glisiretik Asidin İnsan Kronik Miyelojenöz Lösemi Hücreleri Üzerindeki Etkileri
Öz: Amaç: Kronik miyelojenöz lösemi (KML), başlangıçta imatinib (ilk Abl kinaz inhibitörü) ile tedavi edilen bir tür kan kanseridir. Fakat, KML’li bazı hastalar imatinibe karşı direnç geliştirebilmektedir. Değişik yeni nesil ilaçlar geliştirilmiştir, ancak bu problemin üstesinden gelinememiştir. Glisiretik asit (GA), kanser tedavisinde birçok farmakolojik özellik gösteren bitki kaynaklı bir pentasiklik triterpenoiddir. Bu çalışma, GA’nın K562 hücreleri (Bcr-Abl pozitif lösemi) üzerindeki etkilerini araştırmayı amaçlamaktadır. Gereç ve Yöntemler: MTT hücre proliferasyon analizi, GA’nın imatinibe (pozitif kontrol) kıyasla lösemi ve normal kan hücrelerine karşı sitotoksik etkisini değerlendirmek için kullanıldı. Hücre ölümünün tespiti için, apoptotik/nekrotik/sağlıklı hücre analizi K562 hücrelerine karşı yapıldı. GA’nın kinaz inhibe edici aktivitesini araştırmak için, Abl1 kinaz profil tahlili ve moleküler doking çalışmaları yapıldı. Bulgular: GA, 29,2 μM IC50 değeri ile Abl kinaz inhibitör aktivitesi gösterdi ve 6 saatlik tedaviden sonra K562 hücre hattında apoptoza sebep oldu. Sonuç: Mevcut bulgular, bu bitki özütü sınıfının KML tedavisi için potansiyel bir aday olabileceğini göstermektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, ChimedOrchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J69, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, TabarésSeisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M. Global, Regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524-548.
- 2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Formann D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-386.
- 3. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: Priorities for prevention. Carcinogenesis. 2010;31:100-110.
- 4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
- 5. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol Oncol. 2012;6:155-176.
- 6. Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(Suppl 2):41-59.
- 7. Ma X, Yu H. Global burden of cancer. Yale J Biol Med. 2006;79:85-94.
- 8. Altıntop MD, Ciftci HI, Radwan MO, Sever B, Kaplancıklı ZA, Ali TFS, Koga R, Fujita M, Otsuka M, Özdemir A. Design, synthesis, and biological evaluation of novel 1,3,4-thiadiazole derivatives as potential antitumor agents against chronic myelogenous leukemia: Striking effect of nitrothiazole moiety. Molecules. 2017:23.
- 9. Schenk PW, Snaar-Jagalska BE. Signal perception and transduction: The role of protein kinases. Biochim Biophys Acta. 1999;1449:1-24.
- 10. Fabbro D, Fendrich G, Guez V, Meyer T, Furet P, Mestan J, Griffin JD, Manley PW, Cowan-Jacob SW. Targeted therapy with imatinib: An exception or a rule? Handbook of Experimental Pharmacology. 2005;167:361-389.
- 11. Wang Z, Cole PA. Catalytic mechanisms and regulation of protein kinases. Methods Enzymol. 2014;548:1-21.
- 12. Borriello A, Caldarelli I, Bencivenga D, Stampone E, Perrotta S, Oliva A, Della Ragione F. Tyrosine kinase inhibitors and mesenchymal stromal cells: Effects on self-renewal, commitment and functions. Oncotarget. 2017;8:5540-5565.
- 13. Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125:1780-1789.
- 14. Mughal A, Aslam HM, Khan AM, Saleem S, Umah R, Saleem M. BcrAbl tyrosine kinase inhibitors- current status. Infec Agents Cancer. 2013;8:23.
- 15. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208-1215.
- 16. Barouch-Bentov R, Sauer K. Mechanisms of drug-resistance in kinases. Expert Opin Investig Drugs. 2011;20:153-208.
- 17. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinibresistant chronic myeloid leukaemia. Nat Rev Cancer. 2017;7:345-356.
- 18. Giles FJ, O’Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23:1698-1707.
- 19. Salvador JAR, Leal AS, Valdeira AS, Gonçalves BMF, Alho DPS, Figueiredo SAC, Silvestre SM, Mendes VIS. Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment. Eur J Med Chem. 2017;142:130.
- 20. Radwan MO, Ismail MAH, El-Mekkawy S, Ismail NSM, Hanna AG. Synthesis and biological activity of new 18β-glycyrrhetinic acid derivatives. Arab J Chem. 2016;9:390-399.
- 21. Ciftci HI, Ozturk SE, Ali TFS, Radwan MO, Tateishi H, Koga R, Ocak Z, Can M, Otsuka M, Fujita M. The first pentacyclic triterpenoid gypsogenin derivative exhibiting anti-Abl1 kinase and anti-chronic myelogenous leukemia activities. Biol Pharm Bull. 2018;141:570-574.
- 22. Lu Z, Jin Y, Qiu L, Lai Y, Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 2010;290:182-191.
- 23. Sharma G, Kar S, Palit S, Das PK. 18β-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells. J Cell Physiol. 2012;227:1923-1931.
- 24. Zhu J, Chen M, Chen N, Ma A, Zhu C, Zhao R, Jiang M, Zhou J, Ye L, Fu H, Zhang X. Glycyrrhetinic acid induces G1-phase cell cycle arrest in human non-small cell lung cancer cells through endoplasmic reticulum stress pathway. Int J Oncol. 2015;46:981-988.
- 25. Liu D, Song D, Guo G, Wang R, Lv J, Jing Y, Zhao L. The synthesis of 18β-glycyrrhetinic acid derivatives which have increased antiproliferative and apoptotic effects in leukemia cells. Bioorgan Med Chem. 2007;15:5432-5439.
- 26. Pirzadeh S, Fakhari S, Jalili A, Mirzai S, Ghaderi B, Haghshenas V. Glycyrrhetinic Acid induces apoptosis in leukemic HL60 cells through upregulating of CD95 / CD178. Int J Mol Cell Med. 2014;3:272-278.
- 27. Gao Z, Kang X, Hu J, Ju Y, Xu C. Induction of apoptosis with mitochondrial membrane depolarization by a glycyrrhetinic acid derivative in human leukemia K562 cells. Cytotechnology. 2012;64:421-428.
- 28. Ali TF, Iwamaru K, Ciftci HI, Koga R, Matsumoto M, Oba Y, Kurosaki H, Fujita M, Okamoto Y, Umezawa K, Nakao M, Hide T, Makino K, Kuratsu J, Abdel-Aziz M, Abuo-Rahma Gel-D, Beshr EA, Otsuka M. Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine-pyridine-histidine system. Bioorg Med Chem. 2015;23:5476-5482.
- 29. Bayrak N, Yıldırım H, Tuyun AF, Kara EM, Celik BO, Gupta GK, Ciftci HI, Fujita M, Otsuka M, Nasiri HR. Synthesis, computational study, and evaluation of in vitro antimicrobial, antibiofilm, and anticancer activities of new sulfanyl aminonaphthoquinone derivatives. Lett Drug Des Discov. 2017;14:647-661.
- 30. Karabacak M, Altıntop MD, İbrahim Çiftçi H, Koga R, Otsuka M, Fujita M, Özdemir A. Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents. Molecules. 2015;20:19066-19084.
- 31. Tateishi H, Monde K, Anraku K, Koga R, Hayashi Y, Ciftci HI, DeMirci H, Higashi T, Motoyama K, Arima H, Otsuka M, Fujita M. A clue to unprecedented strategy to HIV eradication: “Lock-in and apoptosis.” Sci Rep. 2017;7:8957.
- 32. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62:4236-4243.
- 33. Radwan MO, Sonoda S, Ejima T, Tanaka A, Koga R, Okamoto Y, Fujita M, Otsuka M. Zinc-mediated binding of a low-molecular-weight stabilizer of the host anti-viral factor apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G. Bioorgan Med Chem. 2016;24:4398-4405.
- 34. Koga R, Radwan MO, Ejima T, Kanemaru Y, Tateishi H, Ali TFS, Ciftci HI, Shibata Y, Taguchi Y, Inoue J, Otsuka M, Fujita M. A Dithiol Compound Binds to the Zinc finger protein TRAF6 and suppresses its ubiquitination. ChemMedChem. 2017;12:1935-1941.
| APA | ÇİFTÇİ H (2020). Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. , 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| Chicago | ÇİFTÇİ Halilibrahim Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. (2020): 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| MLA | ÇİFTÇİ Halilibrahim Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. , 2020, ss.49 - 55. 10.4274/tjps.galenos.2018.49389 |
| AMA | ÇİFTÇİ H Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. . 2020; 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| Vancouver | ÇİFTÇİ H Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. . 2020; 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| IEEE | ÇİFTÇİ H "Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells." , ss.49 - 55, 2020. 10.4274/tjps.galenos.2018.49389 |
| ISNAD | ÇİFTÇİ, Halilibrahim. "Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells". (2020), 49-55. https://doi.org/10.4274/tjps.galenos.2018.49389 |
| APA | ÇİFTÇİ H (2020). Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. Turkish Journal of Pharmaceutical Sciences, 17(1), 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| Chicago | ÇİFTÇİ Halilibrahim Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. Turkish Journal of Pharmaceutical Sciences 17, no.1 (2020): 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| MLA | ÇİFTÇİ Halilibrahim Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. Turkish Journal of Pharmaceutical Sciences, vol.17, no.1, 2020, ss.49 - 55. 10.4274/tjps.galenos.2018.49389 |
| AMA | ÇİFTÇİ H Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. Turkish Journal of Pharmaceutical Sciences. 2020; 17(1): 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| Vancouver | ÇİFTÇİ H Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells. Turkish Journal of Pharmaceutical Sciences. 2020; 17(1): 49 - 55. 10.4274/tjps.galenos.2018.49389 |
| IEEE | ÇİFTÇİ H "Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells." Turkish Journal of Pharmaceutical Sciences, 17, ss.49 - 55, 2020. 10.4274/tjps.galenos.2018.49389 |
| ISNAD | ÇİFTÇİ, Halilibrahim. "Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells". Turkish Journal of Pharmaceutical Sciences 17/1 (2020), 49-55. https://doi.org/10.4274/tjps.galenos.2018.49389 |
